FGF-2 Polyclonal Antibody
¥680.00
- 产品信息
商品描述
靶点-Target
JNK2
反应性
Human,Mouse,Rat
应用
WB,IHC,IF,ELISA
宿主物种-Host Species
Rabbit
同种型-Isotype
IgG
修饰-Modification
Unmodified
MW(Observed)
48kD
推荐稀释比
WB 1:500-1:2000;IHC 1:100-1:300;ELISA 1:10000;IF 1:50-200
组成
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
纯化工艺
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
储存
-15°C to -25°C/1 year(Do not lower than -25°C)
浓度
1 mg/ml
克隆性
Polyclonal
免疫原
The antiserum was produced against synthesized peptide derived from human MAPK9. AA range:246-295
特异性
JNK2 Polyclonal Antibody detects endogenous levels of JNK2 protein.
基因名称
MAPK9
蛋白名称
Mitogen-activated protein kinase 9
别名
MAPK9;JNK2;PRKM9;SAPK1A;Mitogen-activated protein kinase 9;MAP kinase 9;MAPK 9;JNK-55;Stress-activated protein kinase 1a;SAPK1a;Stress-activated protein kinase JNK2;c-Jun N-terminal kinase 2
Organism-1
Human
基因ID-1
5601
SwissProt-1
P45984
Organism-2
Mouse
基因ID-2
26420
SwissProt-2
Q9WTU6
Organism-3
Rat
基因ID-3
50658
SwissProt-3
P49186
背景
The protein encoded by this gene is a member of the MAP kinase family. MAP kinases act as an integration point for multiple biochemical signals, and are involved in a wide variety of cellular processes such as proliferation, differentiation, transcription regulation and development. This kinase targets specific transcription factors, and thus mediates immediate-early gene expression in response to various cell stimuli. It is most closely related to MAPK8, both of which are involved in UV radiation induced apoptosis, thought to be related to the cytochrome c-mediated cell death pathway. This gene and MAPK8 are also known as c-Jun N-terminal kinases. This kinase blocks the ubiquitination of tumor suppressor p53, and thus it increases the stability of p53 in nonstressed cells. Studies of this gene's mouse counterpart suggest a key role in T-cell differentiation. Several alternative
细胞定位
Cytoplasm . Nucleus . Colocalizes with POU5F1 in the nucleus. .
